Grünenthal extends gout portfolio with second EU approval

Family-owned German firm Grünenthal has won European approval for Duzallo (lesinurad/allopurinol), a fixed-dose combination therapy for hyperuricemia in adult gout patients.

The Aachen-based drugmaker has been granted the marketing authorization for patients who have not been able to reach target levels of uric acid serum with a dose of allopurinol alone.

Chief scientific officer Philip Just Larsen said: “The unmet need in gout treatment is extremely high. The disease is under-diagnosed, undertreated and significantly reduces the quality of life for patients.”